N/A N=1,154 The Healthy Heart Study
Cardiac Rehabilitation
Primary: Participation in Cardiac Rehabilitation — 231; 252 Participants — p=0.80
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=128 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
Infections, Meningococcal
Primary: Number of Subjects With Any Solicited Adverse Events (AEs) Within 30 Minutes After Each Vaccination. — 0; 0; 0; 1 Participants
N/A N=152 Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
Urinary Incontinence, Urge
Primary: Percent Change in Urgency Urinary Incontinence Episodes — 73; 88.6 percentage change in median UUI episodes — p=<.025
Phase 1 N=29 A Dose-Escalation Study in Participants With Advanced Cancer
Advanced Cancer
Primary: Number of Participants With One or More Drug-related Adverse Events — 1; 0; 1; 0 Participants
Phase 1 N=33 Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Number of Participants Experiencing an Adverse Event (AE) — 6; 6; 0; 4 Participants
N/A N=50 Effectiveness of Two Self Assessment Tools: KIOS-Bipolar or eMoods
Bipolar Disorder
Primary: Comparison of Two Brief Assessment Measures: KIOS Bipolar or eMOODs — 43 Participants
Phase 4 N=52 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Oestrogen Receptor Positive Advanced Breast Cancer
Primary: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer — 39…
N/A N=258 Stroke Self-Management: Effect on Function and Stroke Specific Quality of Life
Stroke
Primary: Total Stroke Specific Quality of Life — 3.80; 3.82; 4.01; 3.94 units on a scale — p=0.0500
Phase 2 N=148 Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
Advanced or Metastatic Breast Cancer · ER+ve Advanced or Metastatic Breast Cancer
Primary: Dose-limiting Toxicity (DLT) Events - Part A — 0; 2; 0; 0 participants
N/A N=692 ABF Tourette's Disorder Post Marketing Surveillance Study
Tourette's Disorder
Primary: Frequency (n) of Subjects With Adverse Event — 50; 19; 42; 14 Participants
Phase 2 N=52 Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
Intestinal Obstruction
Primary: Percentage of Responders Before or at Day 7 — 88.2; 25.7; 46.2 percentage of responders — p=0.0055
Early Phase 1 N=24 Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
Breast Cancer
Primary: Number of Participants With Spot 14 Expression Pre and Post CLA as Assessed by Quantitative Immunohistochemistry and Staining Intensities Scored at 0, 1, or 2 — 0; 0…
Phase 1 N=104 Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Locally Advanced Tumors · Metastatic Solid Tumors · Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0; 0 Participants
Phase 2 N=71 Treatment of Patients With RAD001 With Progressive Sarcoma
Progressive Sarcoma
Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1
Phase 2 N=49 An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: The Change in Injection Site Pain Score Using an 11-point Visual Numeric Scale — -0.35; -0.11 Difference (scores on a scale)